FI105916B - Menetelmä terapeuttisesti käyttökelpoisten 3R-3,7-difenyyli-1,8-diatsaspiro[5,5]undekaanijohdannaisten valmistamiseksi - Google Patents

Menetelmä terapeuttisesti käyttökelpoisten 3R-3,7-difenyyli-1,8-diatsaspiro[5,5]undekaanijohdannaisten valmistamiseksi Download PDF

Info

Publication number: FI105916B
Authority: FI; Finland
Prior art keywords: formula; phenyl; compounds; compound; diazaspiro
Prior art date: 1993-03-04

Application number

FI941022A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI941022A0 (fi

FI941022L (fi

Inventor

Manoj C Desai

Lawrence A Vincent

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-03-04

Filing date

1994-03-03

Publication date

2000-10-31

1994-03-03 Application filed by Pfizer filed Critical Pfizer

1994-03-03 Publication of FI941022A0 publication Critical patent/FI941022A0/fi

1994-09-05 Publication of FI941022L publication Critical patent/FI941022L/fi

2000-10-31 Application granted granted Critical

2000-10-31 Publication of FI105916B publication Critical patent/FI105916B/fi

Links

238000004519 manufacturing process Methods 0.000 title description 3
150000001875 compounds Chemical class 0.000 claims abstract description 81
150000003839 salts Chemical class 0.000 claims description 23
238000006243 chemical reaction Methods 0.000 claims description 15
238000000034 method Methods 0.000 claims description 15
OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims description 12
238000002360 preparation method Methods 0.000 claims description 8
230000008569 process Effects 0.000 claims description 8
RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical class CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 claims description 7
125000001153 fluoro group Chemical group F* 0.000 claims description 5
125000000217 alkyl group Chemical group 0.000 claims description 3
RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 claims description 3
239000012265 solid product Substances 0.000 claims description 3
150000003512 tertiary amines Chemical class 0.000 claims description 3
DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 claims description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
125000001424 substituent group Chemical group 0.000 claims description 2
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 22
208000027866 inflammatory disease Diseases 0.000 abstract description 4
150000003053 piperidines Chemical class 0.000 abstract description 3
208000015114 central nervous system disease Diseases 0.000 abstract description 2
230000002757 inflammatory effect Effects 0.000 abstract description 2
230000015572 biosynthetic process Effects 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 20
QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 18
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
102100024304 Protachykinin-1 Human genes 0.000 description 18
101800003906 Substance P Proteins 0.000 description 18
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
239000011541 reaction mixture Substances 0.000 description 14
208000035475 disorder Diseases 0.000 description 13
125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
239000002904 solvent Substances 0.000 description 11
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
239000000203 mixture Substances 0.000 description 10
-1 2-methoxy-5-trifluoromethoxy-4-phenyl-1-phenyl-1, 8-diaza-spiro [5.5] undecane Chemical compound 0.000 description 9
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
239000002253 acid Substances 0.000 description 9
201000010099 disease Diseases 0.000 description 8
239000007787 solid Substances 0.000 description 8
241000124008 Mammalia Species 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
238000005160 1H NMR spectroscopy Methods 0.000 description 6
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
238000005481 NMR spectroscopy Methods 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
230000000694 effects Effects 0.000 description 5
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 5
230000009467 reduction Effects 0.000 description 5
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
206010015866 Extravasation Diseases 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
239000007983 Tris buffer Substances 0.000 description 4
239000002585 base Substances 0.000 description 4
230000027455 binding Effects 0.000 description 4
MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 4
239000012267 brine Substances 0.000 description 4
230000036251 extravasation Effects 0.000 description 4
239000012044 organic layer Substances 0.000 description 4
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
239000005695 Ammonium acetate Substances 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
241000700198 Cavia Species 0.000 description 3
206010020751 Hypersensitivity Diseases 0.000 description 3
208000022559 Inflammatory bowel disease Diseases 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
102000002002 Neurokinin-1 Receptors Human genes 0.000 description 3
108010040718 Neurokinin-1 Receptors Proteins 0.000 description 3
208000028017 Psychotic disease Diseases 0.000 description 3
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
208000026935 allergic disease Diseases 0.000 description 3
229940043376 ammonium acetate Drugs 0.000 description 3
235000019257 ammonium acetate Nutrition 0.000 description 3
150000003863 ammonium salts Chemical class 0.000 description 3
235000017663 capsaicin Nutrition 0.000 description 3
229960002504 capsaicin Drugs 0.000 description 3
239000003446 ligand Substances 0.000 description 3
230000002265 prevention Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
206010065040 AIDS dementia complex Diseases 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
229910000761 Aluminium amalgam Inorganic materials 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
206010002383 Angina Pectoris Diseases 0.000 description 2
208000019901 Anxiety disease Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
206010057254 Connective tissue inflammation Diseases 0.000 description 2
206010012335 Dependence Diseases 0.000 description 2
201000004624 Dermatitis Diseases 0.000 description 2
208000032131 Diabetic Neuropathies Diseases 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
208000018522 Gastrointestinal disease Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
241000282414 Homo sapiens Species 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
206010047700 Vomiting Diseases 0.000 description 2
239000000556 agonist Substances 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
230000003042 antagnostic effect Effects 0.000 description 2
230000036506 anxiety Effects 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
230000037396 body weight Effects 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
210000002808 connective tissue Anatomy 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
230000002327 eosinophilic effect Effects 0.000 description 2
229960003699 evans blue Drugs 0.000 description 2
239000012458 free base Substances 0.000 description 2
230000009610 hypersensitivity Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
JILPJDVXYVTZDQ-UHFFFAOYSA-N lithium methoxide Chemical compound [Li+].[O-]C JILPJDVXYVTZDQ-UHFFFAOYSA-N 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
208000004296 neuralgia Diseases 0.000 description 2
230000002981 neuropathic effect Effects 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
239000008188 pellet Substances 0.000 description 2
229960001412 pentobarbital Drugs 0.000 description 2
208000033808 peripheral neuropathy Diseases 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
239000002464 receptor antagonist Substances 0.000 description 2
229940044551 receptor antagonist Drugs 0.000 description 2
230000011514 reflex Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
230000000392 somatic effect Effects 0.000 description 2
239000003890 substance P antagonist Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000002889 sympathetic effect Effects 0.000 description 2
230000005062 synaptic transmission Effects 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
201000000596 systemic lupus erythematosus Diseases 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
YNMZZHPSYMOGCI-UHFFFAOYSA-N undecan-3-one Chemical compound CCCCCCCCC(=O)CC YNMZZHPSYMOGCI-UHFFFAOYSA-N 0.000 description 2
230000002455 vasospastic effect Effects 0.000 description 2
239000003039 volatile agent Substances 0.000 description 2
230000008673 vomiting Effects 0.000 description 2
239000008096 xylene Substances 0.000 description 2
150000003738 xylenes Chemical class 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
239000011701 zinc Substances 0.000 description 2
MRXDGVXSWIXTQL-HYHFHBMOSA-N (2s)-2-[[(1s)-1-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-2-[[(2s)-4-methyl-1-oxo-1-[[(2s)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]amino]-2-oxoethyl]carbamoylamino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C1NC(N)=NCC1)C(O)=O)C1=CC=CC=C1 MRXDGVXSWIXTQL-HYHFHBMOSA-N 0.000 description 1
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
FVIVALCKMXCKQX-UHFFFAOYSA-N 1,8-diazaspiro[5.5]undecane Chemical compound N1CCCCC11CNCCC1 FVIVALCKMXCKQX-UHFFFAOYSA-N 0.000 description 1
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
MZCITWGLXKYOGE-UHFFFAOYSA-N 3-(2-methoxyphenyl)prop-2-enyl acetate Chemical compound COC1=CC=CC=C1C=CCOC(C)=O MZCITWGLXKYOGE-UHFFFAOYSA-N 0.000 description 1
ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
241000234282 Allium Species 0.000 description 1
235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
108010001478 Bacitracin Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
OWFKCVDYQRBPFU-UHFFFAOYSA-N C1CCN(C2(C1)CCC(=O)NC2)C3=CC=CC=C3 Chemical compound C1CCN(C2(C1)CCC(=O)NC2)C3=CC=CC=C3 OWFKCVDYQRBPFU-UHFFFAOYSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
OLVPQBGMUGIKIW-UHFFFAOYSA-N Chymostatin Natural products C=1C=CC=CC=1CC(C=O)NC(=O)C(C(C)CC)NC(=O)C(C1NC(N)=NCC1)NC(=O)NC(C(O)=O)CC1=CC=CC=C1 OLVPQBGMUGIKIW-UHFFFAOYSA-N 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
208000027932 Collagen disease Diseases 0.000 description 1
DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
208000030814 Eating disease Diseases 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
208000019454 Feeding and Eating disease Diseases 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
102000003141 Tachykinin Human genes 0.000 description 1
102000007124 Tachykinin Receptors Human genes 0.000 description 1
108010072901 Tachykinin Receptors Proteins 0.000 description 1
206010046543 Urinary incontinence Diseases 0.000 description 1
206010046555 Urinary retention Diseases 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
230000007815 allergy Effects 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000000561 anti-psychotic effect Effects 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
229960003071 bacitracin Drugs 0.000 description 1
229930184125 bacitracin Natural products 0.000 description 1
CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
238000009835 boiling Methods 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
238000011072 cell harvest Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
108010086192 chymostatin Proteins 0.000 description 1
206010009887 colitis Diseases 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000004020 conductor Substances 0.000 description 1
208000018631 connective tissue disease Diseases 0.000 description 1
239000007799 cork Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
201000003146 cystitis Diseases 0.000 description 1
ZAJNGDIORYACQU-UHFFFAOYSA-N decan-2-one Chemical compound CCCCCCCCC(C)=O ZAJNGDIORYACQU-UHFFFAOYSA-N 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
235000014632 disordered eating Nutrition 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
LBAQSKZHMLAFHH-UHFFFAOYSA-N ethoxyethane;hydron;chloride Chemical compound Cl.CCOCC LBAQSKZHMLAFHH-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
238000011597 hartley guinea pig Methods 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
230000002296 hyperlocomotor Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000010410 layer Substances 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
230000004899 motility Effects 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
208000030212 nutrition disease Diseases 0.000 description 1
208000019180 nutritional disease Diseases 0.000 description 1
230000000414 obstructive effect Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
PEUGKEHLRUVPAN-UHFFFAOYSA-N piperidin-3-amine Chemical class NC1CCCNC1 PEUGKEHLRUVPAN-UHFFFAOYSA-N 0.000 description 1
231100000572 poisoning Toxicity 0.000 description 1
230000000607 poisoning effect Effects 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
239000002287 radioligand Substances 0.000 description 1
206010037844 rash Diseases 0.000 description 1
238000010992 reflux Methods 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
229910052702 rhenium Inorganic materials 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
108060008037 tachykinin Proteins 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
125000003944 tolyl group Chemical group 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
RSJKGSCJYJTIGS-BJUDXGSMSA-N undecane Chemical class CCCCCCCCCC[11CH3] RSJKGSCJYJTIGS-BJUDXGSMSA-N 0.000 description 1
210000002700 urine Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Hydrogenated Pyridines (AREA)

FI941022A 1993-03-04 1994-03-03 Menetelmä terapeuttisesti käyttökelpoisten 3R-3,7-difenyyli-1,8-diatsaspiro[5,5]undekaanijohdannaisten valmistamiseksi FI105916B (fi)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US2638293A	1993-03-04	1993-03-04
US2638293		1993-03-04

Publications (3)

Publication Number	Publication Date
FI941022A0 FI941022A0 (fi)	1994-03-03
FI941022L FI941022L (fi)	1994-09-05
FI105916B true FI105916B (fi)	2000-10-31

Family

ID=21831515

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI941022A FI105916B (fi)	1993-03-04	1994-03-03	Menetelmä terapeuttisesti käyttökelpoisten 3R-3,7-difenyyli-1,8-diatsaspiro[5,5]undekaanijohdannaisten valmistamiseksi

Country Status (13)

Country	Link
US (1)	US5688806A (fr)
EP (1)	EP0687268B1 (fr)
JP (1)	JP2832754B2 (fr)
CN (1)	CN1099035A (fr)
AT (1)	ATE166650T1 (fr)
AU (1)	AU6226494A (fr)
CA (1)	CA2157117C (fr)
DE (1)	DE69318854T2 (fr)
DK (1)	DK0687268T3 (fr)
ES (1)	ES2116587T3 (fr)
FI (1)	FI105916B (fr)
IL (1)	IL108769A0 (fr)
WO (1)	WO1994020500A1 (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5393762A (en) *	1993-06-04	1995-02-28	Pfizer Inc.	Pharmaceutical agents for treatment of emesis
EP0655246A1 (fr) *	1993-11-30	1995-05-31	Pfizer Inc.	Antagonistes de la substance P pour le traitement des maladies causées par Helicobacter Pylori ou d'autres bacteries spirales, ureare-positives, gram-négatives
US5696267A (en) *	1995-05-02	1997-12-09	Schering Corporation	Substituted oximes, hydrazones and olefins as neurokinin antagonists
US5688960A (en) *	1995-05-02	1997-11-18	Schering Corporation	Substituted oximes, hydrazones and olefins useful as neurokinin antagonists
TW458774B (en)	1995-10-20	2001-10-11	Pfizer	Antiemetic pharmaceutical compositions
JP2000500760A (ja) *	1995-11-23	2000-01-25	メルクシヤープエンドドームリミテツド	スピロピペリジン誘導体およびタキキニン拮抗薬としてのその使用
GB9603136D0 (en) *	1996-02-15	1996-04-17	Merck Sharp & Dohme	Therapeutic agents
GB9603137D0 (en) *	1996-02-15	1996-04-17	Merck Sharp & Dohme	Therapeutic agents
EE9800309A (et) *	1996-03-14	1999-02-15	Warner-Lambert Company	Uued asendatud tsüklilised aminohapped kui farmatseutilised toimeained
EA001574B1 (ru) *	1996-06-21	2001-06-25	Мерк Шарп Энд Домэ Лимитед	Производные спиропиперидина и их использование в качестве терапевтических агентов
GB9613969D0 (en) *	1996-07-03	1996-09-04	Merck Sharp & Dohme	Therapeutic agents
WO1998013369A1 (fr) *	1996-09-25	1998-04-02	Merck Sharp & Dohme Limited	Derives spiro-azacycliques, preparation de ces derives et leur utilisation comme antagonistes de la tachykinine
GB9625843D0 (en) *	1996-12-12	1997-01-29	Merck & Co Inc	Phenyl spiroethercycloalkyl tachykinn receptor antagonists
US5929094A (en) *	1996-10-25	1999-07-27	Merck & Co., Inc.	Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
US5789422A (en) *	1996-10-28	1998-08-04	Schering Corporation	Substituted arylalkylamines as neurokinin antagonists
US5945428A (en) *	1996-11-01	1999-08-31	Schering Corporation	Substituted oximes, hydrazones and olefins as neurokinin antagonists
WO1998024444A1 (fr) *	1996-12-02	1998-06-11	Merck Sharp & Dohme Limited	Utilisation d'antagonistes du recepteur nk-1 dans le traitement des troubles du sevrage
GB9708484D0 (en) *	1997-04-25	1997-06-18	Merck Sharp & Dohme	Therapeutic agents
GB9711114D0 (en)	1997-05-29	1997-07-23	Merck Sharp & Dohme	Therapeutic agents
US7101547B1 (en)	1999-01-22	2006-09-05	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method for the prevention and treatment of diseases caused by an inflammatory response mediated by endogenous substance P by using anti-substance P antibodies
GB9902881D0 (en)	1999-02-09	1999-03-31	Merck Sharp & Dohme	Therapeutic agents
CA2324116A1 (fr) *	1999-10-25	2001-04-25	Susan Beth Sobolov-Jaynes	Antagonistes du recepteur nk-1 et eletriptan pour le traitement de la migraine
US7163949B1 (en)	1999-11-03	2007-01-16	Amr Technology, Inc.	4-phenyl substituted tetrahydroisoquinolines and use thereof
RU2309953C2 (ru)	1999-11-03	2007-11-10	Эймр Текнолоджи, Инк.	Арил- и гетероарилзамещенные тетрагидроизохинолины, фармацевтическая композиция и способ лечения на их основе
EP1241257A4 (fr)	1999-12-21	2005-03-16	Takeda Pharmaceutical	Polypeptides de type tachykinine et utilisation associee
WO2002004455A2 (fr)	2000-07-11	2002-01-17	Albany Molecular Research, Inc	Tetrahydroisoquinoleines 4-phenyle substituees et leur utilisation therapeutique
US20020049211A1 (en) *	2000-09-06	2002-04-25	Sobolov-Jaynes Susan Beth	Combination treatment for depression and anxiety
EP1192952A3 (fr) *	2000-09-28	2003-03-26	Pfizer Products Inc.	Composition pour le traitement de la dépression et de l'anxieté contenant un antagoniste du recepteur NK-3 et un antagoniste du récepteur NK-1
KR20040029375A (ko) *	2001-07-20	2004-04-06	화이자 프로덕츠 인코포레이티드	개, 고양이 및 말에서 결함있는 행태를 변화시키기 위한ｎｋ-1 수용체 길항제의 용도
US7541357B2 (en)	2004-07-15	2009-06-02	Amr Technology, Inc.	Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
CA2575461A1 (fr) *	2004-08-20	2006-03-02	Targacept, Inc.	Utilisation de composes diazaspiracycliques n-aryle dans le traitement de la toxicomanie
EP1888050B1 (fr)	2005-05-17	2012-03-21	Merck Sharp & Dohme Ltd.	Acide cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl) cyclohexanepropanoique pour le traitement du cancer
JP5258561B2 (ja)	2005-07-15	2013-08-07	アルバニーモレキュラーリサーチ，インコーポレイテッド	アリール置換およびヘテロアリール置換テトラヒドロベンズアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用
CN101277960A (zh)	2005-09-29	2008-10-01	默克公司	作为黑皮质素-4受体调节剂的酰化螺哌啶衍生物
GB0603041D0 (en)	2006-02-15	2006-03-29	Angeletti P Ist Richerche Bio	Therapeutic compounds
EP2698157B1 (fr)	2006-09-22	2015-05-20	Merck Sharp & Dohme Corp.	Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
US20110218176A1 (en)	2006-11-01	2011-09-08	Barbara Brooke Jennings-Spring	Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP2109608B1 (fr)	2007-01-10	2011-03-23	Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A.	Indazoles à substitution amide utilisés comme inhibiteurs de la poly(adp-ribose)polymérase (parp)
JP5319518B2 (ja)	2007-04-02	2013-10-16	Ｍｓｄ株式会社	インドールジオン誘導体
US8389553B2 (en)	2007-06-27	2013-03-05	Merck Sharp & Dohme Corp.	4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US8598184B2 (en)	2008-03-03	2013-12-03	Tiger Pharmatech	Protein kinase inhibitors
US9156812B2 (en)	2008-06-04	2015-10-13	Bristol-Myers Squibb Company	Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (fr)	2009-04-01	2010-10-07	Merck Sharp & Dohme Corp.	Inhibiteurs de l'activité akt
EP2429293B1 (fr)	2009-05-12	2014-10-29	Bristol-Myers Squibb Company	FORMES CRISTALLINES DE (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN -6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE ET LEURS UTILISATIONS
DK2429296T3 (en)	2009-05-12	2018-03-12	Albany Molecular Res Inc	7 - ([1,2,4,] TRIAZOLO [1,5, -A] PYRIDIN-6-YL) -4- (3,4-DICHLORPHENYL) -1,2,3,4- TETRAHYDROISOQUINOLINE AND USE thereof
KR20120034644A (ko)	2009-05-12	2012-04-12	알바니 몰레큘라 리써치, 인크.	아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
BR112012008849A2 (pt)	2009-10-14	2015-09-22	Schering Corp	composto, composição farmacêutica, e, uso de um composto
CN103096893B (zh)	2010-06-04	2016-05-04	阿尔巴尼分子研究公司	甘氨酸转运体-1抑制剂、其制备方法及其用途
WO2011163330A1 (fr)	2010-06-24	2011-12-29	Merck Sharp & Dohme Corp.	Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
EP2601293B1 (fr)	2010-08-02	2017-12-06	Sirna Therapeutics, Inc.	Inhibition à médiation par interférence arn de caténine (protéine associée à cadhérine), expression du gène bêta 1 (ctnnb1) à l'aide de petit acide nucléique interférent (sian)
JP2013537423A (ja)	2010-08-17	2013-10-03	メルク・シャープ・エンド・ドーム・コーポレイション	低分子干渉核酸（ｓｉＮＡ）を用いたＢ型肝炎ウイルス（ＨＢＶ）遺伝子発現のＲＮＡ干渉媒介性阻害
EP2608669B1 (fr)	2010-08-23	2016-06-22	Merck Sharp & Dohme Corp.	Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor
WO2012030685A2 (fr)	2010-09-01	2012-03-08	Schering Corporation	Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
US9242981B2 (en)	2010-09-16	2016-01-26	Merck Sharp & Dohme Corp.	Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (fr)	2010-10-29	2012-05-03	Merck Sharp & Dohme Corp.	INHIBITION FACILITÉE PAR L'INTERFÉRENCE D'ARN DE L'EXPRESSION D'UN GÈNE AU MOYEN D'ACIDES NUCLÉIQUES INTERFÉRENTS COURTS (siNA)
WO2012087772A1 (fr)	2010-12-21	2012-06-28	Schering Corporation	Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
CN103732592A (zh)	2011-04-21	2014-04-16	默沙东公司	胰岛素样生长因子-1受体抑制剂
US9023865B2 (en)	2011-10-27	2015-05-05	Merck Sharp & Dohme Corp.	Compounds that are ERK inhibitors
US20150299696A1 (en)	2012-05-02	2015-10-22	Sirna Therapeutics, Inc.	SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
EP2900241B1 (fr)	2012-09-28	2018-08-08	Merck Sharp & Dohme Corp.	Nouveaux composés inhibiteurs de erk
US20140206667A1 (en)	2012-11-14	2014-07-24	Michela Gallagher	Methods and compositions for treating schizophrenia
AU2013352568B2 (en)	2012-11-28	2019-09-19	Merck Sharp & Dohme Llc	Compositions and methods for treating cancer
TW201429969A (zh)	2012-12-20	2014-08-01	Merck Sharp & Dohme	作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
EP2951180B1 (fr)	2013-01-30	2018-05-02	Merck Sharp & Dohme Corp.	Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
EP3041938A1 (fr)	2013-09-03	2016-07-13	Moderna Therapeutics, Inc.	Polynucléotides circulaires
US10975084B2 (en)	2016-10-12	2021-04-13	Merck Sharp & Dohme Corp.	KDM5 inhibitors
EP3706742B1 (fr)	2017-11-08	2023-03-15	Merck Sharp & Dohme LLC	Inhibiteurs de prmt5
WO2019094312A1 (fr)	2017-11-08	2019-05-16	Merck Sharp & Dohme Corp.	Inhibiteurs de prmt5
BR112021002267A8 (pt)	2018-08-07	2023-02-07	Merck Sharp & Dohme	Inibidores de prmt5
WO2020033284A1 (fr)	2018-08-07	2020-02-13	Merck Sharp & Dohme Corp.	Inhibiteurs de prmt5
WO2020033282A1 (fr)	2018-08-07	2020-02-13	Merck Sharp & Dohme Corp.	Inhibiteurs de prmt5
BR112023022050A2 (pt) *	2021-05-03	2023-12-26	Jazz Pharmaceuticals Ireland Ltd	Agonistas do receptor de orexina e usos destes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0273659A1 (fr) *	1986-12-27	1988-07-06	Takeda Chemical Industries, Ltd.	Composés azaspiro, leur préparation et leur utilisation
EP0311313B1 (fr) *	1987-10-05	1995-05-10	Yamanouchi Pharmaceutical Co. Ltd.	Composés spiro hétérocycliques et leur préparation
EP0360390A1 (fr) *	1988-07-25	1990-03-28	Glaxo Group Limited	Dérivés de spirolactames
WO1990005525A1 (fr) *	1988-11-23	1990-05-31	Pfizer Inc.	Derives de quinuclidine en tant qu'antagonsites de substance p
US5075317A (en) *	1989-06-21	1991-12-24	Fisons Corporation	Spirofurane derivatives
ES2065175T3 (es) *	1991-03-01	1995-02-01	Pfizer	Derivados de 1-azabiciclo(3.2.2)nonan-3-amina.
US5393762A (en) *	1993-06-04	1995-02-28	Pfizer Inc.	Pharmaceutical agents for treatment of emesis

1993
- 1993-12-10 US US08/513,798 patent/US5688806A/en not_active Expired - Fee Related
- 1993-12-10 WO PCT/US1993/011793 patent/WO1994020500A1/fr not_active Ceased
- 1993-12-10 JP JP6519951A patent/JP2832754B2/ja not_active Expired - Fee Related
- 1993-12-10 AT AT94909413T patent/ATE166650T1/de not_active IP Right Cessation
- 1993-12-10 DK DK94909413T patent/DK0687268T3/da active
- 1993-12-10 DE DE69318854T patent/DE69318854T2/de not_active Expired - Fee Related
- 1993-12-10 CA CA002157117A patent/CA2157117C/fr not_active Expired - Fee Related
- 1993-12-10 AU AU62264/94A patent/AU6226494A/en not_active Abandoned
- 1993-12-10 EP EP94909413A patent/EP0687268B1/fr not_active Expired - Lifetime
- 1993-12-10 ES ES94909413T patent/ES2116587T3/es not_active Expired - Lifetime
1994
- 1994-02-24 IL IL10876994A patent/IL108769A0/xx unknown
- 1994-03-03 FI FI941022A patent/FI105916B/fi not_active IP Right Cessation
- 1994-03-03 CN CN94102227A patent/CN1099035A/zh active Pending

Also Published As

Publication number	Publication date
DE69318854T2 (de)	1998-10-08
EP0687268A1 (fr)	1995-12-20
WO1994020500A1 (fr)	1994-09-15
FI941022A0 (fi)	1994-03-03
DK0687268T3 (da)	1998-10-12
FI941022L (fi)	1994-09-05
US5688806A (en)	1997-11-18
EP0687268B1 (fr)	1998-05-27
JP2832754B2 (ja)	1998-12-09
DE69318854D1 (de)	1998-07-02
ATE166650T1 (de)	1998-06-15
CN1099035A (zh)	1995-02-22
IL108769A0 (en)	1994-06-24
CA2157117A1 (fr)	1994-09-15
ES2116587T3 (es)	1998-07-16
AU6226494A (en)	1994-09-26
JPH08503226A (ja)	1996-04-09
CA2157117C (fr)	1999-01-05

Publication	Publication Date	Title
FI105916B (fi)	2000-10-31	Menetelmä terapeuttisesti käyttökelpoisten 3R-3,7-difenyyli-1,8-diatsaspiro[5,5]undekaanijohdannaisten valmistamiseksi
US7098337B2 (en)	2006-08-29	1,2,3,4,9,9a-hexahydro-2,4a,5-triaza-fluorene and 1,2,3,4-tetrahydro-2,4a,5-triaza-fluorene derivatives
US5073560A (en)	1991-12-17	Spiro-isoxazolidine derivatives as cholinergic agents
JP5680101B2 (ja)	2015-03-04	Ｏｒｌ−１受容体アンタゴニストとしてのスピロピペリジン化合物
US7897595B2 (en)	2011-03-01	Pyridoazepine derivatives
AU2004251847B2 (en)	2007-08-23	5HT2c receptor agonists for the treatment of diabetes and obesity
AU2003205622A1 (en)	2003-09-18	Aza-arylpiperazines
US8252930B2 (en)	2012-08-28	Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition
AU2016251517A1 (en)	2017-10-26	Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US6225320B1 (en)	2001-05-01	Spiro-azacyclic derivatives and their use as therapeutic agents
UA124576C2 (uk)	2021-10-13	Циклічні простоефірні похідні піразоло[1,5-a]піримідин-3-карбоксаміду
EP0452101A2 (fr)	1991-10-16	Composés spiro-hétérocycliques portés et non portés
EP2041131B1 (fr)	2011-09-28	Dérivés d'azaindole avec une combinaison d'agonisme partiel du récepteur nicotinique de l'acétylcholine et d'inhibition de la réabsorption de la dopamine
CN108148060B (zh)	2020-06-19	取代的杂环化合物及其衍生物，其药物组合物、制备方法及用途
JP2009504752A (ja)	2009-02-05	治療剤としての縮合三環式ｍＧｌｕＲ１アンタゴニスト
CZ203999A3 (cs)	2000-03-15	Deriváty di- nebo triazaspiro[4,5]dekanu
JP2009504755A (ja)	2009-02-05	治療剤としての縮合三環式ｍＧｌｕＲ１アンタゴニスト
WO2005085228A1 (fr)	2005-09-15	Dérivé cycloalkanopyridine
JP2008521771A (ja)	2008-06-26	改良された抗精神病活性および抗不安症活性を有するイソキサゾリン−インドール誘導体
US6815448B2 (en)	2004-11-09	Azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene as 5-HT1A antagonists
JP2002536436A (ja)	2002-10-29	スピロ環ケトン類およびそれのタキキニン拮抗薬としての使用
TW200819448A (en)	2008-05-01	Azaindole derivatives with a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition

Legal Events

Date	Code	Title	Description
2005-09-30	MA	Patent expired